09:45 AM EDT, 03/24/2025 (MT Newswires) -- AnaptysBio ( ANAB ) shares were up Monday morning after the company said its board approved a stock repurchase plan of up to $75 million, expiring Dec. 31.

The company said that as of Dec. 31, it had cash, cash equivalents and investments of more than $420 million, which are expected to fund its research and development plan through 2027.

The clinical-stage pharmaceutical company said it expects a $75 million commercial sales milestone payment from GSK (GSK) in 2025 or 2026.

Price: 19.94, Change: +2.86, Percent Change: +16.74